Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor

N Calandrella1, G Risuleo, G Scarsella

  • 1Department of Cell Biology and Development, University of Rome La Sapienza, Italy.

Abstract

Insights

The tyrosine kinase inhibitor PD166866 significantly reduces cell proliferation and viability in fibroblasts by inhibiting the basic Fibroblast Growth Factor (bFGF)/Fibroblast Growth Factor Receptor-1 (FGFR-1) pathway, potentially through apoptosis induction.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cell proliferation dysregulation is central to tumor development.
  • Growth factors like basic Fibroblast Growth Factor (bFGF) are implicated in pathologies with uncontrolled cell growth.
  • Targeting specific signaling pathways offers therapeutic potential for proliferative diseases.

Purpose of the Study:

  • To evaluate the effects of PD166866, a potent tyrosine kinase inhibitor, on cell proliferation.
  • To investigate the inhibition of the bFGF/Fibroblast Growth Factor Receptor-1 (FGFR-1) system by PD166866.
  • To assess the impact of PD166866 on fibroblast viability and proliferation.

Main Methods:

  • Utilized cultured murine fibroblasts (3T6 cell line).
  • Assessed FGFR-1 inhibition mediated by PD166866.
  • Employed cell viability assays and molecular biology techniques.
  • Examined chromatin degradation as an indicator of apoptosis.

Main Results:

  • PD166866 demonstrated potent and selective inhibition of FGFR-1.
  • The compound negatively regulated the bFGF/FGFR-1 signaling pathway.
  • Significant reduction in cell proliferation and loss of viability were observed in 3T6 cells.
  • Evidence suggests PD166866 induces apoptosis, indicated by chromatin degradation.

Conclusions:

  • PD166866 effectively inhibits the bFGF/FGFR-1 system, reducing fibroblast proliferation and viability.
  • The drug's mechanism may involve the induction of apoptosis.
  • PD166866 shows potential therapeutic utility in managing fibrotic proliferative diseases and other tumor pathologies.